Background: Imatinib is currently considered the standard first-line therapy for chronic myeloid leukemia. Regarding imatinib's potential for cardiotoxicity, recent studies suggest that the incidence of heart failure after long-term use of imatinib is much lower than what is observed with anthracyclines. Goal: To evaluate the cost-effectiveness of different strategies for cardiotoxicity screening in patients receiving imatinib. Methods: We performed a cost-effectiveness study of different strategies of screening for cardiotoxicity in patients receiving imatinib, the first strategy based on yearly echocardiograms in all patients; the second strategy based on yearly BNP measurement, reserving echocardiograms for patients with an abnormal test.
